[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603036":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":25,"locations":31,"responsibleParty":53,"collaborators":56,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":10,"maxAge":10,"enrollmentInfo":95,"targetDuration":98,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":107,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Lymph intervention",null,[12],"Procedure: Lymphatic intervention",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","Lymphatic intervention","This intervention was made as part of their clinical treatment.",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Vibeke E Hjortdal, Professor","STUDY_DIRECTOR",{"name":24,"affiliation":5,"role":22},"Michael Rahbek Schmidt, Ass. professor, PhD, DMSc",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Sanam Safi-Rasmussen, MD","CONTACT","+4530490641","sanam.safi-rasmussen@regionh.dk",[32],{"facility":33,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Rigshospitalet, Copenhagen University Hospital","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":40,"coordinates":41},"Point",[42,43],12.56553,55.67594,{"lat":43,"lon":42},[46,48,51],{"name":27,"role":28,"phone":47,"phoneExt":10,"email":30},"+45 3049 0641",{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},"Vibeke Hjortdal, Professor","PRINCIPAL_INVESTIGATOR",{"name":52,"role":50,"phone":10,"phoneExt":10,"email":10},"Michael R Schmidt, Ass. Professor, MD",{"type":50,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sanam Safi-Rasmussen","Sanam Safi-Rasmussen, MD & PhD-fellow",[57,60,62,64,66,68,70,72,74,76,78,80,82,84],{"name":58,"class":59},"UZ Leuven, Leuven, Belgium","UNKNOWN",{"name":61,"class":59},"UCL Bruxelles",{"name":63,"class":6},"Lund University Hospital",{"name":65,"class":6},"University Hospital Schleswig-Holstein",{"name":67,"class":6},"University Hospital, Aachen",{"name":69,"class":6},"Deutsches Herzzentrum Muenchen",{"name":71,"class":59},"Universitätsklinikum Erlangen, Erlangen, Bayern, Germany",{"name":73,"class":59},"UZ Gent, Belgium",{"name":75,"class":59},"Hospital for Children and Adolescents, University of Helsinki",{"name":77,"class":59},"Hospital Universitari Vall d'hebron Barcelona, Spain",{"name":79,"class":6},"Children's University Hospital, Ireland",{"name":81,"class":59},"Evelina London Children's Hospital",{"name":83,"class":6},"Guy's and St Thomas' NHS Foundation Trust",{"name":85,"class":59},"Bambin Gesù Hospital IRCCS, Rome, Italy","100603036","european-registry-study-on-lymphatic-interventions-100603036",false,"NCT07131293","European Registry Study on Lymphatic Interventions","European Registry Study on Lymphatic Interventions: Towards Standardized Care in CHD-Related Lymphatic Disorders","EURO-LYMPH","Inclusion Criteria:\n\n* Patients of any age with a confirmed central lymphatic disorder, either in the context of CHD or as a primary lymphatic disorder, verified through lymphatic diagnostics (e.g. lymphatic imaging or relevant biomarkers).\n* Patients who have undergone, or are undergoing, diagnostic lymphatic imaging and\u002For interventional procedures for their lymphatic disorder.\n* Patients who are receiving, or have received, conservative (non-interventional) management for their lymphatic disorder.\n\nExclusion Criteria:\n\n* Patients with isolated peripheral lymphatic disorders not involving the central lymphatic system.\n* Patients with acute postoperative iatrogenic chylothorax (\\\u003C3-4 weeks duration and not requiring intervention).\n* Patients without sufficient clinical documentation to confirm diagnosis, treatment, or follow-up.\n* Patients who decline, or whose legal guardians decline, to provide informed consent (for prospective inclusion).","ALL",{"count":96,"type":97},500,"ESTIMATED","5 Years","OBSERVATIONAL","This European multicenter observational study aims to evaluate the real-world use, timing, and outcomes of lymphatic interventions in patients with congenital heart disease and\u002For primary lymphatic disorders. The study will examine the effectiveness of diagnostic imaging and interventional techniques, such as lymphatic embolization, in improving clinical symptoms, biomarkers, and fluid-related complications. The central question is whether early diagnosis and targeted intervention can lead to clinically meaningful improvements and reduced need for reintervention. Data collected retrospectively and prospectively from participating centers will help identify predictors of outcome, assess disease severity, and inform standardized diagnostic and therapeutic pathways across Europe.",[102,103,104,105,106],"Lymphatic Disorders","Plastic Bronchitis","Protein Losing Enteropathy","Chylothorax","Lymphatic Abnormalities",[108,109,110,104,105],"Lymphatic complications","Multicenter study","Plastic bronchitis","2026-01-19",{"date":113,"type":114},"2026-01-21","ACTUAL",{"date":116,"type":97},"2026-02-01",{"date":118,"type":97},"2030-03",{"name":5,"class":6},1]